Oligodendrogliomda Moleküler Patogenez ve Yeni Nesil Dizilemenin Tanısal Rolü
Synopsis
Oligodendroglioma is an adult-type diffuse glioma defined by the presence of an IDH mutation and whole-arm 1p/19q codeletion. This chapter examines the molecular mechanisms underlying tumor development and the contribution of next-generation sequencing (NGS) to diagnosis. Mutant IDH causes 2-hydroxyglutarate accumulation, leading to epigenetic changes that affect cellular differentiation. Together with this process, 1p/19q codeletion and alterations in the TERT promoter, CIC, and FUBP1 shape the tumor’s biological features. The chapter also addresses clonal evolution and molecular changes associated with progression. In diagnostic practice, immunohistochemistry, chromosomal microarrays, NGS, and DNA methylation profiling provide complementary information, although each method has distinct capabilities and limitations. Distinguishing whole-arm 1p/19q codeletion from partial losses is particularly important for accurate classification. The reliability of NGS results depends on tumor cell content, panel coverage, and analytical validation. Although CDKN2A/B homozygous deletion is associated with an adverse prognosis, it does not independently determine tumor grade in oligodendroglioma. Molecular findings must therefore be interpreted alongside histopathological features and specimen quality. The chapter explains the principles of this integrated approach and the challenges commonly encountered when interpreting diagnostic results.
References
Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro-Oncology. 2021;23(8): 1231–1251. doi:10.1093/neuonc/noab106
Weller M, van den Bent M, Preusser M, et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nature Reviews Clinical Oncology. 2021;18(3): 170–186. doi:10.1038/s41571-020-00447-z
Cancer Genome Atlas Research Network, Brat DJ, Verhaak RGW, et al. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. The New England Journal of Medicine. 2015;372(26): 2481–2498. doi:10.1056/NEJMoa1402121
Suzuki H, Aoki K, Chiba K, et al. Mutational landscape and clonal architecture in grade II and III gliomas. Nature Genetics. 2015;47(5): 458–468. doi:10.1038/ng.3273
Eckel-Passow JE, Lachance DH, Molinaro AM, et al. Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. The New England Journal of Medicine. 2015;372(26): 2499–2508. doi:10.1056/NEJMoa1407279
Sahm F, Reuss D, Koelsche C, et al. Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma. Acta Neuropathologica. 2014;128(4): 551–559. doi:10.1007/s00401-014-1326-7
Horbinski C, Ligon KL, Brastianos P, et al. The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients. Neuro-Oncology. 2019;21(12): 1498–1508. doi:10.1093/neuonc/noz119
Capper D, Reifenberger G, French PJ, et al. EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection. Neuro-Oncology. 2023;25(5): 813–826. doi:10.1093/neuonc/noad008
van den Bent MJ, Franceschi E, Touat M, et al. Updated EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection—Update 1. Neuro-Oncology. 2025;27(2): 331–337. doi:10.1093/neuonc/noae213
Brat DJ, Aldape K, Bridge JA, et al. Molecular Biomarker Testing for the Diagnosis of Diffuse Gliomas: Guideline From the College of American Pathologists in Collaboration With the American Association of Neuropathologists, Association for Molecular Pathology, and Society for Neuro-Oncology. Archives of Pathology & Laboratory Medicine. 2022;146(5): 547–574. doi:10.5858/arpa.2021-0295-CP
Sahm F, Brandner S, Bertero L, et al. Molecular diagnostic tools for the World Health Organization (WHO) 2021 classification of gliomas, glioneuronal and neuronal tumors; an EANO guideline. Neuro-Oncology. 2023;25(10): 1731–1749. doi:10.1093/neuonc/noad100
Jennings LJ, Arcila ME, Corless C, et al. Guidelines for Validation of Next-Generation Sequencing-Based Oncology Panels: A Joint Consensus Recommendation of the Association for Molecular Pathology and College of American Pathologists. The Journal of Molecular Diagnostics. 2017;19(3): 341–365. doi:10.1016/j.jmoldx.2017.01.011
Mellinghoff IK, van den Bent MJ, Blumenthal DT, et al. Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma. The New England Journal of Medicine. 2023;389(7): 589–601. doi:10.1056/NEJMoa2304194
Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321(5897): 1807–1812. doi:10.1126/science.1164382
Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. The New England Journal of Medicine. 2009;360(8): 765–773. doi:10.1056/NEJMoa0808710
Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathologica. 2009;118(4): 469–474. doi:10.1007/s00401-009-0561-9
Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462(7274): 739–744. doi:10.1038/nature08617
Xu W, Yang H, Liu Y, et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell. 2011;19(1): 17–30. doi:10.1016/j.ccr.2010.12.014
Noushmehr H, Weisenberger DJ, Diefes K, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. 2010;17(5): 510–522. doi:10.1016/j.ccr.2010.03.017
Turcan S, Rohle D, Goenka A, et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature. 2012;483(7390): 479–483. doi:10.1038/nature10866
Lu C, Ward PS, Kapoor GS, et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature. 2012;483(7390): 474–478. doi:10.1038/nature10860
Flavahan WA, Drier Y, Liau BB, et al. Insulator dysfunction and oncogene activation in IDH mutant gliomas. Nature. 2016;529(7584): 110–114. doi:10.1038/nature16490
Bunse L, Pusch S, Bunse T, et al. Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate. Nature Medicine. 2018;24(8): 1192–1203. doi:10.1038/s41591-018-0095-6
Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Research. 2006;66(20): 9852–9861. doi:10.1158/0008-5472.CAN-06-1796
Bettegowda C, Agrawal N, Jiao Y, et al. Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science. 2011;333(6048): 1453–1455. doi:10.1126/science.1210557
Yip S, Butterfield YS, Morozova O, et al. Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers. The Journal of Pathology. 2012;226(1): 7–16. doi:10.1002/path.2995
Killela PJ, Reitman ZJ, Jiao Y, et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proceedings of the National Academy of Sciences of the United States of America. 2013;110(15): 6021–6026. doi:10.1073/pnas.1303607110
Bell RJA, Rube HT, Kreig A, et al. The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer. Science. 2015;348(6238): 1036–1039. doi:10.1126/science.aab0015
Aoki K, Nakamura H, Suzuki H, et al. Prognostic relevance of genetic alterations in diffuse lower-grade gliomas. Neuro-Oncology. 2018;20(1): 66–77. doi:10.1093/neuonc/nox132
Spitzer A, Gritsch S, Nomura M, et al. Mutant IDH inhibitors induce lineage differentiation in IDH-mutant oligodendroglioma. Cancer Cell. 2024;42(5): 904–914.e9. doi:10.1016/j.ccell.2024.03.008
Appay R, Dehais C, Maurage CA, et al. CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas. Neuro-Oncology. 2019;21(12): 1519–1528. doi:10.1093/neuonc/noz124
Brat DJ, Aldape K, French PJ, et al. cIMPACT-NOW update 12: Refining pathology-based risk stratification and grading for IDH-mutant gliomas. Neuro-Oncology. 2026;28(9): 2069–2089. doi:10.1093/neuonc/noag108
Tirosh I, Venteicher AS, Hebert C, et al. Single-cell RNA-seq supports a developmental hierarchy in human oligodendroglioma. Nature. 2016;539(7628): 309–313. doi:10.1038/nature20123
Venteicher AS, Tirosh I, Hebert C, et al. Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq. Science. 2017;355(6332): eaai8478. doi:10.1126/science.aai8478
Watanabe T, Nobusawa S, Kleihues P, et al. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. The American Journal of Pathology. 2009;174(4): 1149–1153. doi:10.2353/ajpath.2009.080958
Barthel FP, Johnson KC, Varn FS, et al. Longitudinal molecular trajectories of diffuse glioma in adults. Nature. 2019;576(7785): 112–120. doi:10.1038/s41586-019-1775-1
Labreche K, Simeonova I, Kamoun A, et al. TCF12 is mutated in anaplastic oligodendroglioma. Nature Communications. 2015;6: 7207. doi:10.1038/ncomms8207
Bai H, Harmancı AS, Erson-Omay EZ, et al. Integrated genomic characterization of IDH1-mutant glioma malignant progression. Nature Genetics. 2016;48(1): 59–66. doi:10.1038/ng.3457
Johnson BE, Mazor T, Hong C, et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science. 2014;343(6167): 189–193. doi:10.1126/science.1239947
Touat M, Li YY, Boynton AN, et al. Mechanisms and therapeutic implications of hypermutation in gliomas. Nature. 2020;580(7804): 517–523. doi:10.1038/s41586-020-2209-9
Capper D, Weissert S, Balss J, et al. Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathology. 2010;20(1): 245–254. doi:10.1111/j.1750-3639.2009.00352.x
Reuss DE, Sahm F, Schrimpf D, et al. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an “integrated” diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Acta Neuropathologica. 2015;129(1): 133–146. doi:10.1007/s00401-014-1370-3
Louis DN, Wesseling P, Paulus W, et al. cIMPACT-NOW update 1: Not Otherwise Specified (NOS) and Not Elsewhere Classified (NEC). Acta Neuropathologica. 2018;135(3): 481–484. doi:10.1007/s00401-018-1808-0
Ball MK, Kollmeyer TM, Praska CE, et al. Frequency of false-positive FISH 1p/19q codeletion in adult diffuse astrocytic gliomas. Neuro-Oncology Advances. 2020;2(1): vdaa109. doi:10.1093/noajnl/vdaa109
de Biase D, Acquaviva G, Visani M, et al. Next-Generation Sequencing Panel for 1p/19q Codeletion and IDH1-IDH2 Mutational Analysis Uncovers Mistaken Overdiagnoses of 1p/19q Codeletion by FISH. The Journal of Molecular Diagnostics. 2021;23(9): 1185–1194. doi:10.1016/j.jmoldx.2021.06.004
Capper D, Jones DTW, Sill M, et al. DNA methylation-based classification of central nervous system tumours. Nature. 2018;555(7697): 469–474. doi:10.1038/nature26000
Li MM, Datto M, Duncavage EJ, et al. Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. The Journal of Molecular Diagnostics. 2017;19(1): 4–23. doi:10.1016/j.jmoldx.2016.10.002
Bainbridge MN, Armstrong GN, Gramatges MM, et al. Germline mutations in shelterin complex genes are associated with familial glioma. Journal of the National Cancer Institute. 2015;107(1): dju384. doi:10.1093/jnci/dju384
Miller AM, Shah RH, Pentsova EI, et al. Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid. Nature. 2019;565(7741): 654–658. doi:10.1038/s41586-019-0882-3
Choi C, Ganji SK, DeBerardinis RJ, et al. 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nature Medicine. 2012;18(4): 624–629. doi:10.1038/nm.2682